Geode Capital Management LLC raised its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 35.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 359,640 shares of the biotechnology company’s stock after buying an additional 95,084 shares during the period. Geode Capital Management LLC’s holdings in Heron Therapeutics were worth $5,394,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Wells Fargo & Company MN raised its stake in shares of Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock worth $595,000 after buying an additional 17,442 shares during the last quarter. FMR LLC raised its stake in shares of Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the last quarter. Mesirow Financial Investment Management Equity Management acquired a new stake in shares of Heron Therapeutics during the first quarter worth approximately $435,000. Swiss National Bank raised its stake in shares of Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock worth $1,089,000 after buying an additional 20,700 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock worth $2,861,000 after buying an additional 40,657 shares during the last quarter.
Shares of Heron Therapeutics, Inc. (HRTX) traded up 2.56% during midday trading on Friday, hitting $16.00. The stock had a trading volume of 773,366 shares. Heron Therapeutics, Inc. has a one year low of $12.21 and a one year high of $22.01. The firm’s 50-day moving average is $15.38 and its 200 day moving average is $14.57.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million. On average, analysts predict that Heron Therapeutics, Inc. will post ($3.74) EPS for the current fiscal year.
HRTX has been the subject of a number of research reports. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, May 12th. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 9th. Cowen and Company set a $40.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Aegis restated a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $26.00 price objective on shares of Heron Therapeutics in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $31.00.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
